Drug Discovery World

MARCH 27, 2023

Genomics is driving a revolution in drug development and, in the long run, the state of public healthcare. The first draft human genome took a decade to create, and 13 years to complete. A robust environment will contain secure access controls that can prevent and detect misuse of data.

Genome 52

Genome Genomics Research Scientist 52

Drug Discovery World

MAY 2, 2023

Steve Wowk , VP, Business Unit and General Management of Integrated DNA Technologies, shared with DDW the value of CRISPR-Cas9 in drug discovery. In an effort to defend themselves against viral infection, bacterial cells capture and copy DNA fragments of bacteriophages into their genome. This can be achieved by CRISPR screening.

Genome 52

Genome Genomics Gene DNA 52

XTalks

FEBRUARY 11, 2021

The Human Genome Project recently marked 20 years since the publication of the first full sets of human genomic sequences, an endeavor that spanned well over a decade. Today, new next-generation sequencing technologies allow for the sequencing of complex genomes within just a day or two.

Genetics 119

Genetics DNA Genome Genomics 119

Drug Discovery World

DECEMBER 15, 2022

These platforms all induce double strand cuts in the chromosomal DNA that can be sealed by the cell, leading to a specific gene disruption, or resulting in a new target site for inserting DNA segments. Reduce/eliminate chromosomal disruptions caused by double-strand DNA breaks. In one example, Choi et al.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

The Pharma Data

OCTOBER 19, 2020

Spectrum’s self-contained saliva collection kit provides critical sample consistency while suspending and neutralizing viral RNA transcripts completely inactivating the live virus. ABOUT SPECTRUM SOLUTIONS AND SPECTRUM DNA. Food and Drug Administration (FDA) EUA authorization. Photo: Business Wire).

RNA 52

RNA DNA Engineer Packaging 52

Drug Discovery World

FEBRUARY 8, 2023

This helps ensure a high concentration of loaded capsids and adequate removal of impurities, such as host cell proteins and DNA. In AAV therapeutics, empty capsids are those that are not packaged with the therapeutic DNA. A crucial part of the AAV workflow is the purification of viral vectors.

Gene Therapy 52

Gene Therapy Gene Antibody Production 52